|
Synonyms: BMS-901608 | Empliciti® | HuLuc63
elotuzumab is an approved drug (FDA (2015), EMA (2016))
Compound class:
Antibody
Comment: Elotuzumab is a humanized IgG1 antibody targeting CS1 (SLAMF7) [1-2].
Peptide sequences for elotuzumab are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Following evaluation in Phase 3 clinical trial for MM, which tested various combinations of lenalidomide, dexamethasone or bortezomib ± elotuzumab [3-4], the US FDA approved the elotuzumab/lenalidomide/dexamethasone combination in late 2015. Use is indicated for MM patients who have received one to three prior therapies. In the European Union elotuzumab has had orphan drug designation since August 2012, for the treatment of MM. |
| Mechanism Of Action and Pharmacodynamic Effects |
| CS1 is present in particularly high levels on the plasma cells from patients with MM [2]. Elotuzumab engagement of CS1 effectively activates the body's immune system to attack and kill MM cells by inducing antibody-dependent cellular cytotoxicity (ADCC) against them [2]. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
